News Releases

Therabron Therapeutics to Present at the 2016 Biotech Showcase Conference

ROCKVILLE, Md., Jan. 7, 2016 /PRNewswire/ -- Therabron Therapeutics, Inc., a specialty biotechnology company dedicated to redefining the management of respiratory disease through innovation, today announced that its President and Chief Executive Officer, Dr. Thomas F. Miller, has been invited to give a corporate presentation at the 2016 Biotech Showcase Conference on Tuesday, January 12 at 8:45am (PDT).  The event, now in its eighth year, will take place at the Parc 55 Hotel in San Francisco, California.

Therabron Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2007 and located in Rockville, MD.  Therabron is focused on the advancement of respiratory therapeutics with disease-modifying potential. The company's product candidates aim to restore the natural immune balance in the lungs of respiratory patients through the administration of recombinant human CC10 proteins. The family of CC10 proteins, also known as secretoglobins, have the potential to change the course of acute and chronic respiratory diseases, representing large markets into which few truly novel drugs have been introduced.

Therabron's product candidates have the potential to be first-in-class, disease-modifying, breakthrough biologic therapeutics. For additional information, please visit

About Biotech Showcase 2016

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.

Biotech Showcase is organized by both Demy-Colton Life Science Advisors and the EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry. For more information, go to the EBD Group conference website:

SOURCE Therabron Therapeutics, Inc.

For further information: Michael Parks, Pitch360: 484.356.7105 or